The global non-invasive cancer diagnostics market size is calculated at USD 161.2 billion in 2024, grew to USD 173.13 billion in 2025 and is predicted to hit around USD 329.15 billion by 2034, expanding at a CAGR of 7.40% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-Invasive Cancer Diagnostics Market
5.1. COVID-19 Landscape: Non-Invasive Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-Invasive Cancer Diagnostics Market, By Type
8.1. Non-Invasive Cancer Diagnostics Market, by Type, 2024-2034
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Solid Tumors
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Blood Cancer
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Ovarian Cancer
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Colorectal Cancer
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Other
8.1.7.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Non-Invasive Cancer Diagnostics Market, By Product Type
9.1. Non-Invasive Cancer Diagnostics Market, by Product Type, 2024-2034
9.1.1. Immunochemistry
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Clinical Microbiology
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Point of Care Test (POCT)
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Hematology
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Hemostasis
9.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Non-Invasive Cancer Diagnostics Market, By Test Type
10.1. Non-Invasive Cancer Diagnostics Market, by Test Type, 2024-2034
10.1.1. Urine Test
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Imaging Test
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Computerized Tomography
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Magnetic Resonance Imaging
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Nuclear Medicine Scans
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. X-ray/Mammography
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Ultrasound
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Spectroscopy
10.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Non-Invasive Cancer Diagnostics Market, By Application
11.1. Non-Invasive Cancer Diagnostics Market, by Application, 2024-2034
11.1.1. Blood
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Urine
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Saliva
11.1.3.1. Market Revenue and Forecast (2021-2034)
cast (2021-2034)
Chapter 12. Global Non-Invasive Cancer Diagnostics Market, By End Users
12.1. Non-Invasive Cancer Diagnostics Market, by End Users, 2024-2034
12.1.1. Hospital and Clinics
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Diagnostic Centers
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Ambulatory care
12.1.3.1. Market Revenue and Forecast (2021-2034)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 13. Global Non-Invasive Cancer Diagnostics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.1.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.5. Market Revenue and Forecast, by End Users (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.6.5. Market Revenue and Forecast, by End Users (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Type (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Application (2021-2034)
13.1.7.5. Market Revenue and Forecast, by End Users (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.2.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.5. Market Revenue and Forecast, by End Users (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.2.7. Market Revenue and Forecast, by Application (2021-2034)
13.2.8. Market Revenue and Forecast, by End Users (2021-2034)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.2.10. Market Revenue and Forecast, by Application (2021-2034)
13.2.11. Market Revenue and Forecast, by End Users (2021-2034)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.12.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.12.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.2.12.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.13. Market Revenue and Forecast, by End Users (2021-2034)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2034)
13.2.14.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.2.14.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.2.14.4. Market Revenue and Forecast, by Application (2021-2034)
13.2.15. Market Revenue and Forecast, by End Users (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.3.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.5. Market Revenue and Forecast, by End Users (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.7. Market Revenue and Forecast, by End Users (2021-2034)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.9. Market Revenue and Forecast, by End Users (2021-2034)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.10.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.10.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.3.10.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.10.5. Market Revenue and Forecast, by End Users (2021-2034)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.3.11.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.3.11.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.3.11.4. Market Revenue and Forecast, by Application (2021-2034)
13.3.11.5. Market Revenue and Forecast, by End Users (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.4.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.5. Market Revenue and Forecast, by End Users (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.7. Market Revenue and Forecast, by End Users (2021-2034)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.9. Market Revenue and Forecast, by End Users (2021-2034)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.10.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.10.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.4.10.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.10.5. Market Revenue and Forecast, by End Users (2021-2034)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2034)
13.4.11.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.4.11.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.4.11.4. Market Revenue and Forecast, by Application (2021-2034)
13.4.11.5. Market Revenue and Forecast, by End Users (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.5.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.5. Market Revenue and Forecast, by End Users (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.7. Market Revenue and Forecast, by End Users (2021-2034)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2034)
13.5.8.2. Market Revenue and Forecast, by Product Type (2021-2034)
13.5.8.3. Market Revenue and Forecast, by Test Type (2021-2034)
13.5.8.4. Market Revenue and Forecast, by Application (2021-2034)
13.5.8.5. Market Revenue and Forecast, by End Users (2021-2034)
Chapter 14. Company Profiles
14.1. Abbott
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Thermo Fisher Scientific, Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Illumina, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. QIAGEN
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. F. Hoffmann-La Roche Ltd
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Agilent Technologies, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Quest Diagnostics Incorporated.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Merck KGaA
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Hologic, Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. BD.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client